LMP1 CAR T-cells
Phase 1Cell therapy
LMP1 CAR T-cells is one of 16 small molecule programs targeting Infectious Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Infectious Disease
#DrugCompanyPhaseTrials
1Calquence
AstraZenecaApproved
Cipro
BayerApproved
Maxipime
PfizerApproved
Merrem
BB. Braun Medical Inc.
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Tygacil
PPrism Pharmaceuticals
Preclinical
Avycaz
PPhiladelphia Eye Associates
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LMP1 CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- ZZhejiang University